We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
Read MoreHide Full Article
Shares of Rocket Pharmaceuticals (RCKT - Free Report) have plunged 32.9% in the past six months compared with the industry’s decline of 3.4%.
The company is developing its gene therapy candidate, Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
In June 2024, the FDA issued a complete response letter (CRL) to Rocket’s biologics license application (BLA) seeking approval for Kresladi to treat LAD-I.
Per the CRL, the FDA sought "limited" additional information on the Chemistry Manufacturing and Controls (CMC), which is part of the BLA submission. The goal of CMC is to ensure that every batch of the final product is identical in terms of its safety, purity, potency and performance.
This was the primary reason for the stock’s decline in the said time.
Image Source: Zacks Investment Research
Setbacks in Kresladi Development Plans & Other Pipeline Updates
The abovementioned CRL is the second time the FDA has requested additional information from the company on Kresladi’s CMC. In February 2024, the FDA extended the review period of the Kresladi BLA by an additional three months to review the CMC information.
Apart from Kresladi, Rocket is also evaluating two other gene therapies, namely RP-L102 and RP-L301, for the treatment of fanconi anemia and pyruvate kinase deficiency, respectively. Both candidates are in mid-stage development.
RCKT is evaluating another candidate, RP-A501, in a phase II study for the treatment of Danon disease.
The successful development of Kresladi, along with other pipeline candidates. remains the key focus area for Rocket as the company currently has no approved products in its commercial portfolio. However, the recent CRL is likely to delay the approval timeline for Kresladi.
Any further developmental or regulatory setback related to the ongoing studies will hurt the stock significantly in the future.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10.6%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.5%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.5%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
Shares of Rocket Pharmaceuticals (RCKT - Free Report) have plunged 32.9% in the past six months compared with the industry’s decline of 3.4%.
The company is developing its gene therapy candidate, Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
In June 2024, the FDA issued a complete response letter (CRL) to Rocket’s biologics license application (BLA) seeking approval for Kresladi to treat LAD-I.
Per the CRL, the FDA sought "limited" additional information on the Chemistry Manufacturing and Controls (CMC), which is part of the BLA submission. The goal of CMC is to ensure that every batch of the final product is identical in terms of its safety, purity, potency and performance.
This was the primary reason for the stock’s decline in the said time.
Image Source: Zacks Investment Research
Setbacks in Kresladi Development Plans & Other Pipeline Updates
The abovementioned CRL is the second time the FDA has requested additional information from the company on Kresladi’s CMC. In February 2024, the FDA extended the review period of the Kresladi BLA by an additional three months to review the CMC information.
Apart from Kresladi, Rocket is also evaluating two other gene therapies, namely RP-L102 and RP-L301, for the treatment of fanconi anemia and pyruvate kinase deficiency, respectively. Both candidates are in mid-stage development.
RCKT is evaluating another candidate, RP-A501, in a phase II study for the treatment of Danon disease.
The successful development of Kresladi, along with other pipeline candidates. remains the key focus area for Rocket as the company currently has no approved products in its commercial portfolio. However, the recent CRL is likely to delay the approval timeline for Kresladi.
Any further developmental or regulatory setback related to the ongoing studies will hurt the stock significantly in the future.
Rocket Pharmaceuticals, Inc. Price
Rocket Pharmaceuticals, Inc. price | Rocket Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Rocket currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (ILMN - Free Report) , Krystal Biotech, Inc. (KRYS - Free Report) and Fulcrum Therapeutics, Inc. (FULC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10.6%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 48.5%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.5%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.